Name: NEUGEM™ Lyophilized Powder
Brand: RAPID BIOPHARMA PRIVATE LIMITED
SKU: NEUGEM
Availability: MadeToOrder

BharatSeal order protection

Secure payments

Every payment is processed via Razorpay with PCI-DSS data protection and SSL encryption. We never see your card details.

PayUPIVisaMCAmexRuPayNet BankingWalletsPay Later+ more

Money-back protection

Claim a refund if your order doesn't ship, arrives damaged, or doesn't match the agreed spec. Disputes resolved within 7 working days.

Trade Assurance — coming soon for this seller

This seller has not yet activated Trade Assurance. Pay outside BharatSeal at your own risk — we recommend chatting first to verify.

Only orders placed and paid through BharatSeal can enjoy free protection by 🛡 BharatSeal Trade Assurance.

Description

First-line treatment of locally advanced or metastatic Pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil; first-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC); Treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy; first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines are clinically contraindicated.
Treatment of biliary cancer, bladder cancer, relapsed or refractory testicular cancer, squamous cell carcinoma of the head and neck.

Composition

NEUGEM 200 mg
Each vial contains:
Gemcitabine HCl USP eq. to Gemcitabine 200 mg.
Mannitol IP 200 mg.
Sodium acetate IP 12.5 mg.
NEUGEM 1 gm
Each Vial contains:
Gemcitabine HCl USP eq. to Gemcitabine 1000 mg.
Mannitol IP 1000mg.
Sodium acetate IP 62.5 mg.

Indications and Usage:

First-line treatment of locally advanced or metastatic Pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil; first-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC); Treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy; first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines are clinically contraindicated.
Unlabeled Uses
Treatment of biliary cancer, bladder cancer, relapsed or refractory testicular cancer, squamous cell carcinoma of the head and neck.